Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.

Dmytro Trukhin,Elena Poddubskaya,Andric Zoran,Igor Bondarenko,Serhii Shevnia,Bojan Zaric,Ravishankar Bellala,Chaiyut Charoentum,Luis Figuero Pérez,Felicitas Bullo,Fernanda Rafaela Garcia

Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.

2021

Dmytro Trukhin
Elena Poddubskaya
Andric Zoran
Igor Bondarenko
Serhii Shevnia
Bojan Zaric
Ravishankar Bellala
Chaiyut Charoentum
Luis Figuero Pérez
Felicitas Bullo
Fernanda Rafaela Garcia

e15003Background: Stella Trial is a phase III, multinational, double-blind and randomized study to confirm clinical similarity between MB02 and EU-bevacizumab in patients with stage IIIB/IV no squa...

Keywords:

Internal medicine
Medicine
stage iiib
Oncology
Randomized controlled trial
in patient
Bevacizumab
non-small cell lung cancer (NSCLC)
Biosimilar
non squamous

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations